What Melatonina + B6 Treats: Main Uses and Benefits

The therapeutic application of Melatonina + B6 is primarily directed at managing symptomatic sleep disturbances that arise from a lack of synchrony in the body's internal clock. The primary therapeutic use is applied in addressing sleep timing disturbances.

It is commonly used for conditions involving episodic or fluctuating manifestations of sleep timing misalignment, such as Jet Lag and Shift Work Disorder, and episodic difficulties in achieving sleep at the desired hour. This use is relevant for managing symptoms that interfere with daily comfort, and generally helps patients cope more steadily with the difficult episodes of schedule change.

---

Quick Fact: Relief for Sleep Timing Disruptions

It is applied in addressing the symptomatic cluster of difficulty falling asleep and fragmented sleep. Beyond the nighttime symptoms, the product is relevant in contexts involving symptoms that create noticeable physiological strain, such as daytime fatigue and reduced alertness.

---

Indications Summary

It is commonly used across domains where additional symptomatic support is needed for conditions like Jet Lag, Shift Work Disorder, and temporary sleep onset difficulties linked to a disturbed rhythm. By easing the overall symptom burden, it contributes to improved comfort during periods of heightened symptoms.

Regulatory References

1. National Center for Complementary and Integrative Health (NCCIH) at NIH

Who can and cannot use Melatonina + B6?

This section summarizes the official population eligibility and restriction criteria for Melatonin, typically found in regulatory documents like the Summary of Product Characteristics (SmPC) for licensed European formulations.

Eligibility and Restrictions

Classification	Eligible Population	Restriction/Status
Primary Eligible Group	Adults aged 55 years and over	Licensed for short-term treatment of primary insomnia (prolonged-release formulations).
Pediatric Use	Children and adolescents (under 18)	Safety and efficacy are not established for general use; use is typically restricted to specialist-recommended, specific conditions.

Contraindications (Must NOT Use):

Use of Melatonin is contraindicated for patients with a known hypersensitivity to the active substance or any excipients. Certain product formulations are also contraindicated for patients with rare hereditary problems such as galactose intolerance or glucose-galactose malabsorption.

Populations for Whom Use is Not Recommended:

The medicine is generally not recommended for patients with hepatic impairment, severe renal impairment, or active autoimmune diseases. Additionally, use is not recommended during pregnancy or lactation, and women of childbearing potential should use effective contraception.

Interaction Map: Interactions with other medicines and products

Interaction scope

Classification	Interacting Agents (Official Regulatory Basis)
Pharmacokinetic Modifiers	CYP1A2 Inhibitors (e.g., Fluvoxamine, Cimetidine, Estrogens, Caffeine); CYP1A2 Inducers (Rifampicin, Carbamazepine, Tobacco Smoking, St. John’s Wort).
Pharmacodynamic Enhancers	CNS Depressants (including benzodiazepine-related hypnotics, Thioridazine, Imipramine); Alcohol (Ethanol); Anticoagulants (e.g., Warfarin).
Pyridoxine Interactions	Anticonvulsants (e.g., Phenobarbital, Phenytoin); Levodopa (without a decarboxylase inhibitor).

Mechanistic basis of interactions (only if stated in label): Interactions are primarily rooted in CYP1A2 enzyme inhibition or induction, which significantly alters Melatonin’s plasma concentration ( AUC and C max), and pharmacodynamic synergism resulting in enhanced CNS depression.

Timing-based interaction rules (if applicable): Prostaglandin synthesis inhibitors, such as certain NSAIDs, should be administered at times separate from Melatonin due to their documented ability to suppress endogenous Melatonin levels. Alcohol should not be consumed concurrently with the medicine.

Population-specific interaction notes (if applicable): Patients with documented hepatic impairment are noted to have a greater risk of Melatonin accumulation when combined with CYP1A2 inhibitors, requiring specific caution.

Interaction-related restrictions: Co-administration with the potent CYP1A2 inhibitor Fluvoxamine is generally advised to be avoided by regulatory bodies due to the documented risk of a 17-fold increase in Melatonin exposure. The combination with Alcohol is also advised to be avoided.

Connection to the overall interaction profile: The regulatory interaction profile is primarily defined by the pharmacokinetic instability of Melatonin when combined with potent CYP1A2 modifiers and the risk of additive sedative effects with CNS-depressing substances. These documented statements provide explicit constraints for co-administration, directly defining how specific medicinal products and substances interact with the drug.

Regulation of Circadian Rhythms via MT1/ MT2 Receptors

Melatonina functions as a neurotransmitter analog that selectively binds to MT1 and MT2 receptors, primarily within the suprachiasmatic nucleus ( SCN) of the hypothalamus. This interaction modulates the activity of the central biological clock, inducing a phase-shifting effect and reducing the central alerting drive. This mechanistic cascade leads to predictable physiological adjustments that contribute to the timing of sleep initiation and maintain rhythmicity.

---

Support for Neurotransmitter Synthesis and Metabolic Pathways

Vitamin B6 ( Pyridoxine) serves as an essential cofactor for numerous enzyme systems, notably decarboxylase enzymes. These enzymes are required for the biosynthesis of inhibitory neurotransmitters, including GABA and serotonin. Furthermore, B6 is critical in amino acid metabolism and the Krebs cycle, which supports the molecular components required for specific biochemical processes in neural tissue, including the biosynthesis of endogenous Melatonina.

---

Engagement of Antioxidant Defense

Both compounds contribute to mechanisms that limit the impact of oxidative stress on cells. Melatonina is a direct free radical scavenger and also promotes the activity of endogenous antioxidant enzymes, such as superoxide dismutase. Vitamin B6, in its active form PLP, contributes to the synthesis of glutathione, supporting a more regulated state within targeted pathways that limits cellular damage.

How to Use Melatonina + B6: Official Administration Guidelines

This section outlines the official usage instructions for the Melatonin and Pyridoxine combination, based strictly on prescribing information. The content focuses solely on how the medicine must be taken, without addressing therapeutic benefits or safety information.

---

Official Administration Protocol

The Melatonina + B6 combination is intended for oral use only. The official instructions define a specific, short-term usage pattern to align with its chronobiotic function.

Administration Detail	Official Requirement (Label-Based)
Route of Administration	Oral use (Tablets or Capsules).
Standard Dosing Range	Typically 2 mg to 3 mg of Melatonin once daily. For Jet Lag, the dose is often 3 mg, or up to 6 mg if needed.
Frequency and Timing	Once daily, taken 1 to 2 hours before the intended bedtime.
Intake Condition	Must be taken after food.
Required Action	Tablets should be swallowed whole with fluid and must not be crushed or chewed (especially for prolonged-release formulations).

---

Duration and Specific Use Contexts

This medication is officially designated for short-term treatment only. For conditions such as Jet Lag, the duration is typically limited to a maximum of 5 days. Prolonged use must be consistent with the specific product's approved label.

Population-Specific Notes

• Older Adults (Elderly): No mandatory dose adjustment is typically required.
• Pediatric Patients: Use in children and adolescents aged 0–18 years is not recommended for general sleep disturbances, unless specifically approved for an alternate indication.

Consistent adherence to the designated daily timing is essential for proper administration.

Research evidence / Overview of studies for Melatonina + B6

Evidence for Use in Jet Lag

The active ingredient was studied for conditions characterized by temporary physiological imbalance following rapid travel across time zones. The primary evidence base consists of short-term Randomized Controlled Trials (RCTs) and pooled Meta-analyses conducted in generally healthy adult travelers. Research primarily examined outcomes related to systemic or functional imbalance, such as the overall subjective severity of jet lag symptoms and the timing of sleep onset.

Studies report how symptoms evolved in the observed populations and included findings describing patterns observed in subjective jet lag severity measurements. The reported outcomes were short-term, typically covering a follow-up duration of less than two weeks. The magnitude of the difference was reported as minimal in some published studies.

Evidence for Use in Managing Shift Work and Temporary Sleep Onset Difficulties

The active ingredient was evaluated in Systematic Reviews and controlled trials for exploring changes in sleep patterns in individuals whose schedules disrupt their natural body clock. Research examined reported daytime sleepiness, sleep quality, and the duration of Sleep Onset Latency (SOL).

In studies focusing on temporary sleep onset challenges, research explored whether Sleep Onset Latency was shorter in some studied groups. Evidence quality varies across studies for these indications, and research describes that the measured difference in outcomes was reported as minimal in some published studies across various adult groups.

Evidence in Special Populations and Research Gaps

Research has explored outcomes in older adults experiencing primary sleep difficulties and in specific groups of children and adolescents with sleep-related conditions. It is important to understand that the results apply only to the populations studied, and Data for certain groups remain insufficient, particularly for areas such as pregnant populations.

The evidence is primarily based on the research conducted for Melatonin as a single-active ingredient. Comparative evidence is lacking to clearly define the specific contribution of Pyridoxine (Vitamin B6) in this fixed-dose combination product for the studied indications.

Key Studies & References National Center for Complementary and Integrative Health (NCCIH): Melatonin Overview

Common questions about Melatonina + B6 (FAQ)

Q: Can Melatonina + B6 cause vivid dreams or nightmares?

Regulatory documents describe vivid dreams or nightmares as potential side effects associated with the active ingredient. Official product information, based on clinical data, describes this possibility.

Q: Is it common to develop tolerance to Melatonina + B6 over time?

Official product information notes that this product is generally designated for short-term use only. Safety reviews, particularly in the context of prolonged use, have noted risks like dependence and withdrawal, which are safety concerns addressed in relation to use over time.

Q: Is there a risk of dependence when taking Melatonina + B6?

Regulatory safety reviews indicate that risks associated with long-term use include the potential for dependence and withdrawal symptoms. Official guidance related to long-term use includes safety considerations, which may involve a review of treatment after specific durations.

Q: What is the safety profile of Melatonina + B6 for use in teenagers?

Official instructions state that use in children and adolescents aged 0–18 years is not recommended for general sleep disturbances, as safety and efficacy have not been established for this broad group. However, the product may be specifically approved for an alternate indication following specialist advice.

Q: How does Melatonina + B6 relate to the body's natural sleep-wake cycle?

The active ingredient is classified as a chronobiotic agent, which means it works to regulate the body's internal clock. It functions as a neurotransmitter analog that modulates the central biological clock, inducing a phase-shifting effect that contributes to the natural timing of sleep initiation.

Q: Do you need a prescription from a doctor to get Melatonina + B6?

The regulatory status of this product varies by country and formulation (e.g., immediate-release vs. prolonged-release). Depending on the region's specific regulatory approach, it may be classified and marketed as a dietary supplement, an over-the-counter (OTC) product, or a prescription-only medicine.

Q: How long does it typically take for the effects of Melatonina + B6 to begin?

Official administration instructions define the timing as 1 to 2 hours before the intended bedtime. Clinical studies have found that the active ingredient may result in an average reduction in the time taken to fall asleep, a measurement known as sleep onset latency.

Q: Can Melatonina + B6 be taken during the day?

The product is directed for use once daily, 1 to 2 hours before the intended bedtime to align with its chronobiotic function. Regulatory warnings note that engaging in activities requiring full attention requires caution, due to the risk of drowsiness.

Q: Does Melatonina + B6 cause a 'hangover' feeling the next morning?

Regulatory documents classify Somnolence (drowsiness) and Daytime drowsiness as common side effects of the active ingredient. These effects can persist into the morning and may contribute to a lingering feeling of grogginess or reduced alertness.

Q: Can Melatonina + B6 affect mood or anxiety levels?

Official labels list Irritability and Anxiety as uncommon adverse reactions. Additionally, regulatory information notes that potential adverse effects may include a short-term feeling of depression and mood swings.

Q: Is it possible for Melatonina + B6 to interact with birth control pills?

The interaction map lists Estrogens (a key component of many hormonal contraceptives) as a pharmacokinetic modifier. The listing of Estrogens as a modifier indicates that the combination may alter the active ingredient’s concentration in the body.

Q: Is it true that taking Melatonina + B6 can affect my immune system?

Regulatory documents state the product is not recommended for patients with Autoimmune Diseases. Research also notes the active ingredient's role as an immunomodulatory compound in some studied biological systems.

Q: Is it normal to feel a tingling sensation after taking a B6 supplement with melatonin?

A tingling, burning, or numbness sensation is a known side effect of the Pyridoxine (B6) component, often referred to as peripheral neuropathy. Regulatory safety advisories note this is typically associated with high doses or prolonged use of B6.

Q: Does Melatonina + B6 have an effect on blood pressure?

The official label lists Hypertension (high blood pressure) as an uncommon adverse reaction associated with use. Clinical studies have also explored the active ingredient's effects on blood pressure regulation, noting that it may interfere with certain antihypertensive agents.

Q: Why do official sources sometimes recommend taking Melatonina + B6 at a specific time?

The specific timing of 1 to 2 hours before bedtime is recommended because the product is a chronobiotic agent. This function works by modulating the body’s central clock, and the precise timing is necessary to initiate the desired phase-shifting effect that supports sleep initiation.

Q: Are there any known food or drink interactions with Melatonina + B6?

Official instructions mandate that the medicine must be taken after food. Furthermore, the consumption of Alcohol is specifically advised to be avoided as it may enhance the sedative effects of the product.

Q: Does Melatonina + B6 help with waking up in the middle of the night?

Research has primarily examined outcomes related to Sleep Onset Latency (the time it takes to fall asleep). The available evidence base is less defined regarding consistent effects on sleep maintenance, which is the ability to stay asleep without waking up in the middle of the night.

Q: What is the mechanism by which B6 is thought to complement melatonin?

Pyridoxine (B6) is considered an essential cofactor for the enzyme systems required for the biosynthesis of inhibitory neurotransmitters in the nervous system. It is also critical for the biosynthesis of the body’s endogenous Melatonina, which is why it is thought to support the overall sleep-wake cycle.

Q: Do official documents mention any potential for withdrawal symptoms if Melatonina + B6 is stopped suddenly?

Regulatory safety reviews note that risks associated with long-term use include the potential for dependence and withdrawal symptoms. Official guidance related to long-term use includes safety considerations, which may involve a review of treatment after specific durations.

Q: How long does Melatonina + B6 stay in the body?

Official patient information often does not include the specific rate at which the active ingredient is removed from the body (half-life). The primary instruction given on patient-facing labels is that the product is officially designated for short-term treatment only.

Q: Can I take Melatonina + B6 while also taking common pain relievers?

The official interaction map explicitly mentions NSAIDs (a common class of pain relievers, like ibuprofen) as substances that should be administered at times separate from the active ingredient. This is due to their documented ability to potentially suppress the body's natural Melatonin levels.

Q: What is meant by a 'research benefit' of Melatonina + B6?

A research benefit refers to the specific positive outcomes observed and measured in clinical trials. This may include the overall subjective severity of jet lag symptoms, the duration of Sleep Onset Latency, or the entrainment of circadian rhythms in the studied groups.

Q: What happens if I forget to take Melatonina + B6 at the designated time?

Official patient information and general drug safety advice states that if a dose is missed at the usual time, the patient should skip that dose and not take double or extra doses to make up for the missed one.

Q: What are the signs of an allergic reaction to Melatonina + B6 described in regulatory information?

Regulatory documents list a rare reaction of Angioedema (swelling of the face or tongue). General patient safety guidance describes signs of a serious allergic reaction as including difficulty breathing, sudden confusion, or the appearance of a severe rash.

Q: Can Melatonina + B6 affect energy levels during the day?

Regulatory documents classify Somnolence (drowsiness) and Asthenia (fatigue) as adverse reactions that can affect alertness and energy levels during the day. Regulatory warnings note that engaging in activities requiring full attention requires caution.

How to Store and Dispose of Melatonina + B6?

The storage and disposal of this combination product are governed by official regulatory instructions focused on maintaining stability and environmental protection.

Official Storage Requirements

Condition	Requirement (Official Labeling)
Temperature	Store at ambient temperature, typically not exceeding 25 C or 30 C.
Protection	Protect from light and moisture; store in a dry place.
Packaging	Keep in the original, tightly sealed container to maintain quality.
Child Safety	Keep out of the sight and reach of children (Mandatory).

Disposal Instructions

Expiration dates on the package define the product's stable shelf-life. Expired or unused medication must be handled according to local pharmaceutical waste rules. Official guidelines mandate that the product must not be flushed down the toilet or poured into any drain. The recommended disposal method is to use authorized community drug take-back programs.